MEDI4893∗ promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4526-4532

  Hua, L ^a   Cohen, T S ^a   Shi, Y ^a   Datta, V ^a   Hilliard, J J ^a   Tkaczyk, C ^a   Suzich, J ^a   Stover, C K ^a   Sellman, B R ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MEDI 4893; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; NEUTRALIZING ANTIBODY; SUVRATOXUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL OVERGROWTH; CELL DAMAGE; CONTROLLED STUDY; FEMALE; LUNG; LUNG ALVEOLUS EPITHELIUM CELL; LUNG INJURY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; STAPHYLOCOCCAL PNEUMONIA; SURVIVAL RATE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; MICROBIOLOGY; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; FEMALE; IMMUNOCOMPROMISED HOST; LINEZOLID; LUNG; MICE; MICE, INBRED C57BL; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; VANCOMYCIN;

EID: 84939824533     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00510-15     Document Type: Article

References (31)

1. Quartin AA, Scerpella EG, Puttagunta S, Kett DH. 2013. A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis 13:561. http://dx.doi.org/10.1186/1471-2334-13-561.
2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29:996-1011. http://dx.doi.org/10.1086/591861.
3. Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. 2012. Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Rev Respir Med 6:533-555. http://dx.doi.org/10.1586/ers.12.45.
4. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58:1108-1117. http://dx.doi.org/10.1128/AAC.02190-13.
5. Ragle BE, Bubeck Wardenburg J. 2009. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77:2712-2718. http://dx.doi.org/10.1128/IAI.00115-09.
6. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, Bee C, Wu S, Pham A, Zeng Z, Pons J, Rajpal A, Shelton D. 2013. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus α-hemolysin. J Mol Biol 425:1641-1654. http://dx.doi.org/10.1016/j.jmb.2013.02.008.
7. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK. 2014. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6:262ra155. http://dx.doi.org/10.1126/scitranslmed.3009655.
8. Berube BJ, Bubeck Wardenburg J. 2013. Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins (Basel) 5:1140-1166. http://dx.doi.org/10.3390/toxins5061140.
9. Inoshima I, Inoshima N, Wilke GA, Powers ME, Frank KM, Wang Y, Bubeck Wardenburg J. 2011. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med 17:1310-1314. http://dx.doi.org/10.1038/nm.2451.
10. Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-Tekippe E, Ting JP, Duncan JA. 2009. Staphylococcus aureus α-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 4:e7446. http://dx.doi.org/10.1371/journal.pone.0007446.
11. Kebaier C, Chamberland RR, Allen IC, Gao X, Broglie PM, Hall JD, Jania C, Doerschuk CM, Tilley SL, Duncan JA. 2012. Staphylococcus aureus α-hemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 inflammasome. J Infect Dis 205:807-817. http://dx.doi.org/10.1093/infdis/jir846.
12. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin. J Infect Dis 206:352-356. http://dx.doi.org/10.1093/infdis/jis192.
13. Inoshima N, Wang Y, Bubeck Wardenburg J. 2012. Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol 132:1513-1516. http://dx.doi.org/10.1038/jid.2011.462.
14. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF. 2014. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem 289:29874-29880. http://dx.doi.org/10.1074/jbc.M114.601328.
15. Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524. http://dx.doi.org/10.1074/jbc.M604292200.
16. Hilliard JJ, Datta V, Tkaczyk C, Hamilton M, Sadowska A, Jones-Nelson O, O'Day T, Weiss WJ, Szarka S, Nguyen V, Prokai L, Suzich J, Stover CK, Sellman BR. 2015. Anti-alpha toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob Agents Chemother 59:299-309. http://dx.doi.org/10.1128/AAC.03918-14.
17. Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. 2013. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 57:6147-6153. http://dx.doi.org/10.1128/AAC.01285-13.
18. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171-5180. http://dx.doi.org/10.4049/jimmunol.169.9.5171.
19. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. 2007. Poring over pores: α-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13:1405-1406. http://dx.doi.org/10.1038/nm1207-1405.
20. Kollef MH, Ward S. 1998. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 113:412-420. http://dx.doi.org/10.1378 /chest.113.2.412.
21. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. 2005. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128:3854-3862. http://dx.doi.org/10.1378/chest.128.6.3854.
22. Song Y, Baer M, Srinivasan R, Lima J, Yarranton G, Bebbington C, Lynch SV. 2012. PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis 31:1837-1845. http://dx.doi.org/10.1007/s10096-011-1509-2.
23. Parker D, Prince A. 2011. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 45:189-201. http://dx.doi.org/10.1165/rcmb.2011-0011RT.
24. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P. 2005. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc Natl Acad Sci USA102:9182-9187. http://dx.doi.org/10.1073/pnas.0500918102.
25. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. 2013. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57:5104-5111. http://dx.doi.org/10.1128/AAC.01230-13.
26. Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA. 2006. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 26:539-550. http://dx.doi.org/10.1592/phco.26.4.539.
27. Woods C, Colice G. 2014. Methicillin-resistant Staphylococcus aureus pneumonia in adults. Expert Rev Respir Med 8:641-651. http://dx.doi.org/10.1586/17476348.2014.940323.
28. R Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). J Antimicrob Chemother 69:1582-1588. http://dx.doi.org/10.1093/jac/dkt541.
29. Tewhey R, Gu B, Kelesidis T, Charlton C, Bobenchik A, Hindler J, Schork NJ, Humphries RM. 2014. Mechanisms of linezolid resistance among coagulase-negative staphylococci determined by whole-genome sequencing. mBio 5(3):e00894-14. http://dx.doi.org/10.1128/mBio.00894-14.
30. Mendes RE, Deshpande LM, Bonilla HF, Schwarz S, Huband MD, Jones RN, Quinn JP. 2013. Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio. Antimicrob Agents Chemother 57:2923-2928. http://dx.doi.org/10.1128/AAC.00071-13.
31. Malachowa N, Kobayashi SD, Braughton KR, Whitney AR, Parnell MJ, Gardner DJ, Deleo FR. 2012. Staphylococcus aureus leukotoxin GH promotes inflammation. J Infect Dis 206:1185-1193. http://dx.doi.org/10.1093/infdis/jis495.